Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
ASTEC

Astec Lifesciences Share Price

 

 

Astec Lifesciences live price: ₹720.8. It opened at ₹740 vs previous close ₹734; intraday high/low: ₹740/₹706. The 50 & 200 DMA stand at ₹636.61/₹709.39.

Astec Lifesciences Performance

  • Today's Low
  • ₹706
  • Today's High
  • ₹740
  • 52 Week Low
  • ₹513
  • 52 Week High
  • ₹991
  • Open Price₹740
  • Previous Close₹734
  • Volume39,157
  • 50 DMA₹636.61
  • 100 DMA₹655.39
  • 200 DMA₹709.39

Astec Lifesciences Chart

Investment Returns

  • Over 1 Month + 37.56%
  • Over 3 Month + 26.58%
  • Over 6 Month + 7.86%
  • Over 1 Year -1.72%

Smart Investing Starts Here Start SIP with Astec Lifesciences for Steady Growth!

Invest Now

Astec Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -18
  • PEG Ratio
  • -0.7
  • Market Cap Cr
  • 1,606
  • P/B Ratio
  • 4
  • Average True Range
  • 39.79
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 21.98
  • RSI
  • 61.56
  • MFI
  • 96.48

Astec Lifesciences Financials

Astec Lifesciences Technicals

EMA & SMA

Current Price
₹720.80
-13.6 (-1.85%)
pointer
  • Bearish Moving Average 1
  • Bullish Moving Average 15
  • 20 Day
  • ₹658.42
  • 50 Day
  • ₹636.61
  • 100 Day
  • ₹655.39
  • 200 Day
  • ₹709.39

Resistance and Support

722.17 Pivot Speed
  • R3 772.48
  • R2 756.17
  • R1 738.48
  • S1 704.48
  • S2 688.17
  • S3 670.48

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Astec Lifesciences Ltd. manufactures agrochemical products, including fungicides, herbicides, and intermediates. With advanced production facilities in India, it serves agricultural sectors globally, offering high-quality crop protection solutions to enhance farm productivity and sustainability.

Astec Lifesciences has an operating revenue of Rs. 409.05 Cr. on a trailing 12-month basis. An annual revenue de-growth of -17% needs improvement, Pre-tax margin of -37% needs improvement, ROE of -57% is poor and needs improvement. The company has a high debt to equity of 119%, which can be a reason to worry. The stock from a technical standpoint is trading close to its 200DMA and around 18% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 39 which is a POOR score indicating inconsistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 96 indicates it belongs to a poor industry group of Chemicals-Agricultural and a Master Score of B is close to being the best. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Astec Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-04-27 Audited Results
2026-01-30 Quarterly Results
2025-10-29 Quarterly Results
2025-07-28 Quarterly Results
2025-06-30 Right Issue of Equity Shares

Astec Lifesciences F&O

Astec Lifesciences Shareholding Pattern

71.97%
3.02%
0.03%
0%
20.81%
4.17%

Astec Lifesciences FAQs

Astec Lifesciences share price is ₹720 As on 25 April, 2026 | 14:24

The Market Cap of Astec Lifesciences is ₹1606.1 Cr As on 25 April, 2026 | 14:24

The P/E ratio of Astec Lifesciences is -18 As on 25 April, 2026 | 14:24

The PB ratio of Astec Lifesciences is 4 As on 25 April, 2026 | 14:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23